PMID- 35715960
OWN - NLM
STAT- MEDLINE
DCOM- 20220804
LR  - 20220916
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Print)
IS  - 1759-7706 (Linking)
VI  - 13
IP  - 15
DP  - 2022 Aug
TI  - Second-line lurbinectedin as a new treatment option for small-cell lung cancer: 
      Preliminary results in real-clinical practice.
PG  - 2248-2252
LID - 10.1111/1759-7714.14464 [doi]
AB  - INTRODUCTION: Few strategies exist for treatment of patients with small-cell lung 
      cancer (SCLC) extended-stage after failure of first-line platinum-based 
      chemotherapy. Lurbinectedin is a novel RNA-polymerase-II inhibitor investigated 
      as a second-line therapy for SCLC. However, its efficacy and safety profile in 
      real clinical practice remain to be determined. OBJECTIVE: To determine the 
      efficacy and safety of lurbinectedin in real-life among patients with SCLC 
      previously treated with first-line platinum-based chemotherapy. METHODS: We 
      retrospectively evaluated patients who received at least one dose of 
      lurbinectedin (3.2 mg/m(2) ) between March 2020 and November 2021, in the 
      pulmonary department of Bordeaux University Hospital. Endpoints were time to 
      treatment discontinuation, progression-free survival, overall survival, and 
      safety profile. RESULTS: Thirteen patients were included. The median age was 
      60 years (range: 42-77), seven (54%) were females, nine (69%) having a 
      performance status of 0-1. Lurbinectedin was given as second-line treatment 
      before platinum rechallenge in four (31%) patients. After a mean follow-up of 
      4.1 months, the objective response rate (ORR) was 17%. The median time to 
      treatment discontinuation (TTD) was 2.3 months (interquartile range [IQR], 
      1.2-3.6). The median progression-free survival (PFS) and overall survival (OS) 
      were, respectively, 1.9 (IQR, 0.1.8) and 4.1 (IQR, 2.0-3.5) months. No 
      significant difference regarding TTD, PFS or OS was found in the two groups 
      according to treatment history or according to chemotherapy-free intervall (CMI) 
      <1 or >1 month. The most common adverse events (AEs) were asthenia, nausea, and 
      anemia in nine (70%) patients. Grade 3 AEs were reported, fatigue, vomiting, 
      nausea, anorexia, and neutropenia. CONCLUSIONS: Lurbinectedin in real clinical 
      practice could have had a lower efficacy than in phase II trial, but a better 
      hematological and bioclinical tolerance than previously reported. Early relapse 
      after platinum-based chemotherapy seems to have a lower response to 
      lurbinectedin.
CI  - (c) 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and 
      John Wiley & Sons Australia, Ltd.
FAU - Toublanc, Anne-Claire
AU  - Toublanc AC
AUID- ORCID: 0000-0001-8224-5279
AD  - Pulmonary Department, Pole Cardio-thoracique, CHU de Bordeaux, Bordeaux, France.
FAU - Guecamburu, Marina
AU  - Guecamburu M
AD  - Pulmonary Department, Pole Cardio-thoracique, CHU de Bordeaux, Bordeaux, France.
FAU - Veillon, Remi
AU  - Veillon R
AD  - Pulmonary Department, Pole Cardio-thoracique, CHU de Bordeaux, Bordeaux, France.
FAU - Rosellini, Pietro
AU  - Rosellini P
AD  - Pulmonary Department, Pole Cardio-thoracique, CHU de Bordeaux, Bordeaux, France.
AD  - INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, Bordeaux, France.
FAU - Girodet, Pierre-Olivier
AU  - Girodet PO
AD  - Pulmonary Department, Pole Cardio-thoracique, CHU de Bordeaux, Bordeaux, France.
AD  - INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, Bordeaux, France.
AD  - Centre de Recherche Cardio-thoracique de Bordeaux, Univ-Bordeaux, Bordeaux, 
      France.
FAU - Zysman, Maeva
AU  - Zysman M
AD  - Pulmonary Department, Pole Cardio-thoracique, CHU de Bordeaux, Bordeaux, France.
AD  - INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, Bordeaux, France.
AD  - Centre de Recherche Cardio-thoracique de Bordeaux, Univ-Bordeaux, Bordeaux, 
      France.
LA  - eng
PT  - Journal Article
DEP - 20220617
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
RN  - 0 (Carbolines)
RN  - 0 (Heterocyclic Compounds, 4 or More Rings)
RN  - 0 (PM 01183)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Carbolines
MH  - Female
MH  - Heterocyclic Compounds, 4 or More Rings
MH  - Humans
MH  - *Lung Neoplasms
MH  - Male
MH  - Middle Aged
MH  - Nausea
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - *Neutropenia
MH  - Retrospective Studies
MH  - *Small Cell Lung Carcinoma
PMC - PMC9346176
OTO - NOTNLM
OT  - lurbinectedin
OT  - safety profile
OT  - salvage chemotherapy
OT  - small cell lung cancer
COIS- No conflict of interest.
EDAT- 2022/06/19 06:00
MHDA- 2022/08/05 06:00
PMCR- 2022/08/01
CRDT- 2022/06/18 01:43
PHST- 2022/04/24 00:00 [revised]
PHST- 2022/03/10 00:00 [received]
PHST- 2022/04/25 00:00 [accepted]
PHST- 2022/06/19 06:00 [pubmed]
PHST- 2022/08/05 06:00 [medline]
PHST- 2022/06/18 01:43 [entrez]
PHST- 2022/08/01 00:00 [pmc-release]
AID - TCA14464 [pii]
AID - 10.1111/1759-7714.14464 [doi]
PST - ppublish
SO  - Thorac Cancer. 2022 Aug;13(15):2248-2252. doi: 10.1111/1759-7714.14464. Epub 2022 
      Jun 17.